Cardiff Oncology Inc (CRDF) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cardiff Oncology Inc (CRDF) has a cash flow conversion efficiency ratio of -0.131x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.97 Million) by net assets ($45.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Cardiff Oncology Inc for the company's overall valuation and market capitalisation.
Cardiff Oncology Inc - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Cardiff Oncology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cardiff Oncology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cardiff Oncology Inc ranked by their cash flow conversion efficiency. Explore Cardiff Oncology Inc earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Western Asset Investment Grade Defined Opportunity Closed Fund
NYSE:IGI
|
N/A |
|
JAKS Resources Bhd
KLSE:4723
|
-0.007x |
|
Ilyang Pharmaceutical Co.,Ltd
KO:007575
|
-0.026x |
|
ITEK Inc
KQ:119830
|
0.034x |
|
Maronan Metals Ltd
AU:MMA
|
-0.179x |
|
Bailador Technology Investments Ltd
AU:BTI
|
-0.039x |
|
Rithm Property Trust Inc.
NYSE:RPT
|
-0.002x |
|
Amber International Holding Limited
NASDAQ:AMBR
|
-0.008x |
Annual Cash Flow Conversion Efficiency for Cardiff Oncology Inc (2009–2025)
The table below shows the annual cash flow conversion efficiency of Cardiff Oncology Inc from 2009 to 2025. View today's stock price for Cardiff Oncology Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $45.39 Million | $-37.92 Million | -0.836x | -83.87% |
| 2024-12-31 | $82.95 Million | $-37.69 Million | -0.454x | -2.60% |
| 2023-12-31 | $69.74 Million | $-30.89 Million | -0.443x | -39.26% |
| 2022-12-31 | $106.34 Million | $-33.82 Million | -0.318x | -93.82% |
| 2021-12-31 | $140.42 Million | $-23.04 Million | -0.164x | -28.89% |
| 2020-12-31 | $128.16 Million | $-16.31 Million | -0.127x | +92.98% |
| 2019-12-31 | $7.31 Million | $-13.27 Million | -1.815x | -38.63% |
| 2018-12-31 | $10.08 Million | $-13.20 Million | -1.309x | +63.42% |
| 2017-12-31 | $6.51 Million | $-23.28 Million | -3.578x | -127.89% |
| 2016-12-31 | $19.77 Million | $-31.04 Million | -1.570x | -245.73% |
| 2015-12-31 | $48.70 Million | $-22.12 Million | -0.454x | +70.21% |
| 2014-12-31 | $8.35 Million | $-12.73 Million | -1.524x | -324.83% |
| 2013-12-31 | $20.39 Million | $-7.32 Million | -0.359x | +84.23% |
| 2012-12-31 | $2.17 Million | $-4.93 Million | -2.275x | -598.70% |
| 2011-12-31 | $-4.23 Million | $-1.93 Million | 0.456x | +9.10% |
| 2010-12-31 | $-5.00 Million | $-2.09 Million | 0.418x | +28.84% |
| 2009-12-31 | $-3.79 Million | $-1.23 Million | 0.325x | -- |
About Cardiff Oncology Inc
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in… Read more